Immunovia announces completion of preferential rights issue of SEK 28.7 million, adding to previously SEK 189.9 million directed issue
(LUND, Sweden) ― Immunovia AB, the Swedish molecular diagnostics company, announces today that it has successfully completed its SEK 28.7 million rights issue of which the subscription period ended on Monday October 17th. The underwriters, who had guaranteed 52% of the rights issue, will thereby not be assigned any shares through their guarantee.285,072 new shares, representing 86.5% of the rights issue of maximum 329,451 new shares, were subscribed with preferential rights. Demand for excess shares by rights holders amounted to 184,969 new shares, of which only 44,379 new shares could be